We present a 68-year-old male patient with persistent and complicated SARS-CoV-2 infection who was diagnosed with acute myeloid leukemia (AML). The patient suffered from fever, cough and progressive dyspnea for 10 days and he was admitted to the intensive care unit due to respiratory failure and cytokine release syndrome (CRS). Despite a transient improvement of CRS by the implementation of supportive care, including also the administration of recombinant tissue plasminogen activator (rt-PA) and tocilizumab, his clinical course worsened over time. Thus, a bone marrow aspiration was performed revealing the presence of myeloblasts in a proportion of 32% and flow cytometry confirmed the diagnosis of AML-M1 according to FAB classification. Re-evaluation of peripheral blood tests revealed that the patient was admitted with anemia and thrombocytopenia that were never recovered during hospitalization. Due to the patient’s poor clinical condition, no chemotherapy was applied, and he died of sepsis and multi-organ failure two days later. This case suggests that in all patients with a persistent and/or complicated infection, even during pandemics, the presence of an underlying hematologic malignancy should always be taken into consideration.
【저자키워드】 COVID-19, acute myeloid leukemia, 【초록키워드】 Anemia, Respiratory failure, intensive care, Hospitalization, Tocilizumab, SARS-COV-2 infection, Infection, Diagnosis, Sepsis, cough, flow cytometry, Cytokine release syndrome, Bone marrow, Peripheral blood, Chemotherapy, Clinical course, Fever, implementation, Dyspnea, male, Patient, Pandemics, leukemia, AML, CRS, supportive care, administration, Hematologic malignancy, multi-organ failure, clinical condition, re-evaluation, tissue plasminogen activator, died, proportion, the patient, diagnosed, applied, was performed, suffered, worsened, 【제목키워드】 SARS-CoV-2, myeloid,